US · Healthcare · Medical Instruments & Supplies
EPS came in at 2.11 against a street estimate of 1.75 — a beat of 20.6%.
Analysts rate ICU Medical Inc a buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $193.38.
CONFIDENT Q2 revenue $548M (+6% organic), adjusted EBITDA $110M (+10% YoY). Raised FY26 EPS guidance to $8.60–$9.00 (vs. street $9.34). Systems growth 12%, Consumables flat at 5% organic. Targeting 2x leverage by year-end. Q2 FY26 North America drove growth; international impacted by OEM wind-down. Currency headwinds (Costa Rican Colon, Mexican Peso, Japanese Yen) created ~$60M drag over 4 years. Analysts pressed on systems growth sustainability, Medfusion timing, and earlier installations. Management clarified growth driven by competitive wins, not replacement cycle. Reaffirmed organic growth at/above 6% near-term; Medfusion timing left vague (this year only). 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.01% |
| Jupiter Topco LLC | 11.12% |
| Vanguard Portfolio Management, LLC | 5.88% |
| Fuller & Thaler Asset Management Inc | 5.19% |
| Vanguard Capital Management, LLC | 4.49% |
| Dimensional Fund Advisors, Inc. | 4.21% |
| State Street Corp | 4.10% |
| Schroder Investment Management Group | 2.96% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $560,439 thousand, up from $536,990 thousand in the third quarter of 2025. • Nine-month revenue wa | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 GAAP revenue was $560.4 million, up from $537.0 million in the third quarter of 2025. • GAAP gross profit incr | 2026-11-05 |
| Quarterly report · Q2 2026 ICU MEDICAL, INC. – FORM 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Total Revenues (6 months): $1,081.9 million (down from $1,153.6 million in | 2026-08-06 |
| Results announced · Q3 2026 ICU MEDICAL Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 GAAP revenue: $551.7 million (up 1% YoY); organic revenue growth 6% excluding IV So | 2026-08-06 |
| Charter / bylaws change · Q2 2026 ICU MEDICAL, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 13, 2026 • All seven director nominees elected with stro | 2026-05-18 |
| Quarterly report · Q1 2026 ICU MEDICAL, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues Q1 2026: $530.2 million (down 12.3% from $604.7 million in Q1 2025) • Gro | 2026-05-07 |
| Results announced · Q2 2026 ICU MEDICAL Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 GAAP Revenue: $530.2 million, down 12% year-over-year from $604.7 million in Q1 2025 | 2026-05-07 |
| Proxy statement · Q2 2026 ICU MEDICAL, INC. – 2026 PROXY SUMMARY CEO COMPENSATION & CHANGES • CEO total compensation figure not disclosed in provided document excerpts • Docu | 2026-04-02 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ICU Medical Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.